Results for tag: "Tecentriq"

Tecentriq (atezolizumab) is a monoclonal antibody drug used to treat certain types of non-small cell lung cancer (NSCLC). It is a type of immunotherapy, which works by helping the body’s immune system recognize and attack cancer cells. Tecentriq is approved for use in combination with chemotherapy for the first-line treatment of metastatic NSCLC, and as a monotherapy for the treatment of locally advanced or metastatic NSCLC in patients whose tumors have high PD-L1 expression. It is also approved for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of metastatic squamous NSCLC. Tecentriq is marketed by Genentech, a subsidiary of Roche, and is available in the United States, Europe, and other countries. Other companies in the lung cancer drug market include AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer. Show Less Read more